Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders. The work of these grantees aims to help increase social connections for underserved students,

Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity

Chesapeake Energy

Foot Locker

LyondellBasell Industries

Newell Brands

Philip Morris

U.S. Bancorp

Nobody was really surprised when the August consumer price index showed yet another month of rising prices.

7 Surprising Stocks With Fat Dividends That Offer Some Very Solid Inflation Protection

AbbVie

Abbott Labs

These stocks offer more than just dividends.

3 Unstoppable Dividend Stocks to Buy in September

Gilead Sciences (NASDAQ: GILD ) is up about 5% on Monday, with GILD stock jumping on news the company is finally settling a patent lawsuit. The settlement involves Gilead's generic HIV drugs, Descovy and Odefsey, as well as its Hepatitis B drug, Vemlidy.

Why Is Gilead Sciences (GILD) Stock Up Today?

Shares of Gilead Sciences Inc. GILD, +0.28% were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its HIV franchise. The drug cited in the case is tenofovir alafenamide, which is included in the formulation of several Gilead therapies, including Biktarvy and Truvada.

Gilead's stock jumps 5% after setting patent case related to HIV therapies

Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.

Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival

Gilead Sciences, Inc. (NASDAQ:GILD ) 2022 Wells Fargo Healthcare Conference September 8, 2022 10:25 AM ET Company Participants Andrew Dickinson - CFO Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. Thank you very much for this session.

Gilead Sciences, Inc. (GILD) Presents at 2022 Wells Fargo Healthcare Conference - (Transcript)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the positive overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians' choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In the study, Trodelvy demonstrated a statistically significant and clinically meani

Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication

SANTA MONICA, Calif.--(BUSINESS WIRE)--KITE'S CAR T-CELL THERAPY TECARTUS® GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Kite's CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.

Gilead (GILD) Announces Positive New Data on Breast Cancer Drug

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapies (physicians' choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. The analysis examined progression-free survival (PFS) in the intention-to-tre

New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status

Johnson & Johnson

One word describes these three stocks and their dividends -- solid.

3 Great Dividend Stocks to Buy in September

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Gilead (GILD) Up 1.9% Since Last Earnings Report: Can It Continue?

Gilead Sciences stock (NASDAQ: GILD) has seen a 14% fall this year, in line with the 15% fall for the broader S&P500 index.

What's Happening With Gilead Sciences Stock?

Gilead Sciences is focused on building up its new businesses, which, despite struggles in the area, are growing at break-neck paces. The company has a single-digit P/E ratio and an almost 5% dividend yield. It's continuing to buy back shares and pay down debt.

Gilead Sciences: Don't Miss The Transformation

Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.

Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?

Amgen

Bristol-Myers

CVS Health

Eli Lilly

Merck

Pfizer

The stock market rally ran into the harsh reality last Friday that any interest rate pivot by the Federal Reserve may not come until 2024.

8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022

Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022

Enbridge

These are both growing dividend stocks with strong underlying businesses.

Want $1,100 in Passive Income? Invest $20,000 in These 2 Stocks

Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval

In the current market environment, investors are arguably well advised to overweight quality and underweight growth. Gilead Sciences trades attractively at a one-year forward P/E below x10. And amidst a turbulent market, the stock has shown strength.

Gilead Sciences: Checking The 4 Pillars Of A Value Stock

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted Marketing Authorization for Sunlenca® (lenacapavir) injection and tablets for the treatment of HIV infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. Lenacapavir is a first-in-class capsid inhibitor with a multi-stage mech

Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

After a long period of flat sales and Biktarvy ramped up while cannibalising its HIV peers, finally HIV produces nice growth. However, now Veklury, the vaunted first COVID-19 treatment, is the black sheep and drags on results.

Gilead Has To Keep Playing The Exclusion Game

Johnson & Johnson is a quintessential dividend growth stock. However, its spinoff plan creates some uncertainties ahead. For investors looking for alternative dividend ideas in the healthcare space, Gilead might appear to be a viable contender.

News for Gilead Sciences Stock (GILD)